yahoo_financeOriginal article
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Data ReadoutpositivesefaxersenPositive
AI Analysis
Summary
Roche announced positive interim data demonstrating that sefaxersen significantly reduces proteinuria in patients with IgA nephropathy (IgAN).
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Interim data shows sefaxersen significantly reduces proteinuria in patients with IgA nephropathy
Importance:7/10
Sentiment:
0.80
IgA nephropathyproteinuriainterim dataclinical trial
Related Companies
Read the original article
Published by yahoo_finance on September 23, 2026 5:15 AM